trial

A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia

NCTId NCT04712734
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 42 (actual)
Sponsored by Vanda Pharmaceuticals
Primary completion 2022-08-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
42 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2021-01-13
Primary completion
2022-08-30
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Iloperidone

Sponsors

Vanda PharmaceuticalsLead Sponsor

Sites

3 total
Garden Grove, United StatesGaithersburg, United StatesMarlton, United States

Facts & assertions

4 sourced
Enrollment
42
Phase
PHASE1
Primary Completion Date
2022-08-30
Status
COMPLETED
relationships
The graph out of here
drug
Iloperidone
drug
lead_sponsor
Vanda Pharmaceuticals
company
indication
Schizophrenia
indication
Schizophrenia
indication